Global Male Hypogonadism Market By Type (Primary (Klinefelter syndrome, Mumps orchitis, Hemochromatosis, Others)Secondary (Kallmann's syndrome, Pituitary disorders, Inflammatory Diseases, Others) By Therapy (Testosterone replacement therapy(Topical Gel, Injections, Implantable pellets, Transdermal Patches, Others) Gonadotropin-releasing Hormones Therapy) By Diagnosis (Hormone Testing, Semen Analysis, Pituitary Imaging, Genetic Studies, Testicular Biopsy); By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
Male hypogonadism is a disorder in which the body produces insufficient amounts of the hormone testosterone, which is important for male growth and development during puberty. According to recent research, testosterone production declines steadily as people age, albeit the rate of drop varies. Unlike women, who experience a sudden drop in hormone levels following menopause, men experience a gradual, steady drop. According to the Baltimore Longitudinal Study of Aging, roughly 20% of men in their 60s and 50% of men in their 80s are hypogonadal. Due to awareness initiatives launched by numerous government bodies throughout the world, the prevalence of testosterone shortage among men is increasing, as is the rate of infertility. Moreover, the leading players in the male hypogonadism market are introducing a range of therapy alternatives, utilising various dosage formulations and giving patients with the greatest solutions for their needs. Individuals are also becoming more aware of hypogonadism treatment. Furthermore, the increased frequency of chronic illnesses among the geriatric population, as well as the elevated risk of hypogonadism among the geriatric population due to obesity and diabetes, are projected to enhance the market's growth.
In terms of revenue, global male hypogonadism market was valued at US$ 3.5 Bn in 2021 growing at a CAGR of 5.7% over the forecast period (2022 – 2030). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Male Hypogonadism Market Revenue & Forecast, (US$ Million), 2015 – 2030
Type Outlook
Based on the type outlook, the global male hypogonadism is segmented into primary and secondary. In many circumstances, clinicians use gonadotropin levels to determine if a patient has primary or secondary male hypogonadism. The term "primary male hypogonadism" refers to a condition caused by faulty gonads. Turner syndrome and Klinefelter syndrome are two separate kinds of primary male hypogonadism. Pituitary or hypothalamus gland abnormalities induce secondary male hypogonadism. Kallmann syndrome and hypopituitarism are two of them. In the last few years, secondary hypogonadism is rapidly rising amongst men. The development of this condition is multifactorial and is linked to chronic disorders such as obesity, type 2 diabetes, and the metabolic syndrome. Thus with rising awareness and early detection the global male hypogonadism market is estimated to grow at rapid pace in the upcoming years.
Therapy Outlook
Based on the therapy, the market is segmented into testosterone replacement therapy and gonadotropin-releasing hormones therapy. Testosterone replacement therapy has the highest share in the market and is primarily being used. The United States Food and Drug Administration has approved testosterone replacement therapy (TRT) as a treatment option for men who lack or have low testosterone levels in addition to a medical condition. TRT is used to restore serum testosterone levels to a physiological range appropriate for the patient's age and to alleviate symptoms in hypogonadal males. Due to its various health benefits such as improved cardiac health and muscle strength, this therapy is being widely adopted and recommended by doctors. TRT administration was found to be able to reverse some of the aforementioned effects to some extent in a sample of hypogonadal men, according to research. Many patients, particularly those with limited mobility, claimed that these impacts improved their quality of life. Leading players in the male hypogonadism market are introducing various products in the form of gel and patches for testosterone replacement therapy. These gel products are gaining quite popularity due to their easy and hassle-free application. There are many different gels and solutions to choose from, each with its own technique of application. The gel containing testosterone has to be rubbed into the skin of upper arm or shoulder or apply it to the front and inner thigh depending on the instructions. On the other hand, nasal sprays and gels are also been used by huge population. This testosterone gel is injected through the nostrils. Nasal testosterone must be applied three times per day, twice in each nostril, which is more time consuming than other methods. Furthermore, buccal tablets are also widely being used by a huge population as peak testosterone levels are quickly established with this method, and a steady state is reached by the second dose after twice-daily administration. Thus various forms of deliveries has led to the growth of global male hypogonadism market.
Region Outlook
Based on the regions, North America registered for a large share of the worldwide male hypogonadism market and is projected to continue to do so in the near future. This is mostly due to an increase in the number of people suffering from primary and secondary hypogonadism, as well as increased awareness of treatment options for the condition. Moreover obesity is one of the major public health issues in North America, since it is associated with a higher morbidity and is a leading cause for the rising cases of male hypogonadism. Furthermore, the availability of cutting-edge healthcare infrastructure and the growing popularity of technologically advanced products are projected to provide new chances for market leaders.
Competitive Landscape
The report provides both, qualitative and quantitative research of global male hypogonadism market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the players operating in the global male hypogonadism market are
- AbbVie
- Antares Pharma, Inc.
- Aytu BioScience, Inc.
- Clarus Therapeutics, Inc.
- Eli Lilly and Company
- Endo Pharmaceuticals
- Merck & Co. Inc.
- Pharmacia & Upjohn Co. (Pfizer Inc.)
- Teva Pharmaceutical Industries Ltd
- Upsher-Smith Laboratories, LLC.
- Other Market Participants
Global Male Hypogonadism Market:
By Type
- Primary
- Klinefelter syndrome
- Mumps orchitis
- Hemochromatosis
- Others
- Secondary
- Kallmann's syndrome
- Pituitary disorders
- Inflammatory Diseases
- Others
By Therapy
- Testosterone replacement therapy
- Topical Gel
- Injections
- Implantable pellets.
- Transdermal Patches
- Others
- Gonadotropin-releasing hormones therapy
By Diagnosis
- Hormone testing
- Semen analysis
- Pituitary imaging
- Genetic studies
- Testicular biopsy
By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2021
1.2.2. Base
Year: 2021
1.2.3. Forecast
Years: 2022 – 2030
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Male Hypogonadism Market
6. Market Synopsis: Male
Hypogonadism Market
7. Male Hypogonadism
Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4. Challenges
7.3. Trends in
Male Hypogonadism Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Male Hypogonadism Market
7.6. Porter’s
Five Force Analysis
7.7. Impact of
Covid-19 on Male Hypogonadism Market
8. Global Male Hypogonadism
Market Analysis and Forecasts, 2022 – 2030
8.1. Overview
8.1.1. Global
Male Hypogonadism Market Revenue (US$
Mn)
8.2. Global
Male Hypogonadism Market Revenue (US$
Mn) and Forecasts, By Type
8.2.1. Primary (Definition, Market Estimation and
Penetration, 2015 - 2021, Market Estimation (2015 - 2021), Market Forecast (2022
– 2030), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North
America, Europe, Asia Pacific, Middle East and Africa, Latin America) and
Information on Klinefelter syndrome, Mumps orchitis, Hemochromatosis, Others )
8.2.1.1. Klinefelter syndrome
8.2.1.2. Mumps orchitis
8.2.1.3. Hemochromatosis
8.2.1.4. Others
8.2.2. Secondary (Definition, Market Estimation and
Penetration, 2015 - 2021, Market Estimation (2015 - 2021), Market Forecast (2022
– 2030), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North
America, Europe, Asia Pacific, Middle East and Africa, Latin America) and
Information on Kallmann’s syndrome, Pituitary disorders, Inflammatory
Diseases , Others )
8.2.2.1. Kallmann’s syndrome
8.2.2.2. Pituitary disorders
8.2.2.3. Inflammatory Diseases
8.2.2.4. Others
8.3. Key
Segment for Channeling Investments
8.3.1. By Type
9. Global Male Hypogonadism
Market Analysis and Forecasts, 2022 – 2030
9.1. Overview
9.2. Global
Male Hypogonadism Market Revenue (US$
Mn) and Forecasts, By Therapy
9.2.1. Testosterone
replacement therapy (Definition, Market Estimation and Penetration, 2015 - 2021,
Market Estimation (2015 - 2021), Market Forecast (2022 – 2030), Compound Annual
Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific,
Middle East and Africa, Latin America) and Information on Topical Gel,
Injections, Implantable pellets., Transdermal Patches, Others)
9.2.1.1. Topical Gel
9.2.1.2. Injections
9.2.1.3. Implantable pellets.
9.2.1.4. Transdermal Patches
9.2.1.5. Others
9.2.2. Gonadotropin-releasing
hormones therapy
9.2.2.1. Definition
9.2.2.2. Market Estimation and Penetration, 2015 - 2021
9.2.2.3. Market Forecast, 2022 – 2030
9.2.2.4. Compound Annual Growth Rate (CAGR)
9.2.2.5. Regional Bifurcation
9.2.2.5.1. North America
9.2.2.5.1.1. Market
Estimation, 2015 - 2021
9.2.2.5.1.2. Market
Forecast, 2022 – 2030
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2015 - 2021
9.2.2.5.2.2. Market
Forecast, 2022 – 2030
9.2.2.5.3. Asia Pacific
9.2.2.5.3.1. Market
Estimation, 2015 - 2021
9.2.2.5.3.2. Market
Forecast, 2022 – 2030
9.2.2.5.4. Middle East and Africa
9.2.2.5.4.1. Market
Estimation, 2015 - 2021
9.2.2.5.4.2. Market
Forecast, 2022 – 2030
9.2.2.5.5. Latin America
9.2.2.5.5.1. Market
Estimation, 2015 - 2021
9.2.2.5.5.2. Market
Forecast, 2022 – 2030
9.3. Key
Segment for Channeling Investments
9.3.1. By
Therapy
10. Global Male Hypogonadism
Market Analysis and Forecasts, 2022 – 2030
10.1. Overview
10.2. Global
Male Hypogonadism Market Revenue (US$
Mn) and Forecasts, By Diagnosis
10.2.1. Hormone
testing
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 - 2021
10.2.1.3. Market Forecast, 2022 – 2030
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market
Estimation, 2015 - 2021
10.2.1.5.1.2. Market
Forecast, 2022 – 2030
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2015 - 2021
10.2.1.5.2.2. Market
Forecast, 2022 – 2030
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market
Estimation, 2015 - 2021
10.2.1.5.3.2. Market
Forecast, 2022 – 2030
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market
Estimation, 2015 - 2021
10.2.1.5.4.2. Market
Forecast, 2022 – 2030
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market
Estimation, 2015 - 2021
10.2.1.5.5.2. Market
Forecast, 2022 – 2030
10.2.2. Semen
analysis
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 - 2021
10.2.2.3. Market Forecast, 2022 – 2030
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market
Estimation, 2015 - 2021
10.2.2.5.1.2. Market
Forecast, 2022 – 2030
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2015 - 2021
10.2.2.5.2.2. Market
Forecast, 2022 – 2030
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market
Estimation, 2015 - 2021
10.2.2.5.3.2. Market
Forecast, 2022 – 2030
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market
Estimation, 2015 - 2021
10.2.2.5.4.2. Market
Forecast, 2022 – 2030
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market
Estimation, 2015 - 2021
10.2.2.5.5.2. Market
Forecast, 2022 – 2030
10.2.3. Pituitary
imaging
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2015 - 2021
10.2.3.3. Market Forecast, 2022 – 2030
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1. Market
Estimation, 2015 - 2021
10.2.3.5.1.2. Market
Forecast, 2022 – 2030
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2015 - 2021
10.2.3.5.2.2. Market
Forecast, 2022 – 2030
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1. Market
Estimation, 2015 - 2021
10.2.3.5.3.2. Market
Forecast, 2022 – 2030
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1. Market
Estimation, 2015 - 2021
10.2.3.5.4.2. Market
Forecast, 2022 – 2030
10.2.3.5.5. Latin America
10.2.3.5.5.1. Market
Estimation, 2015 - 2021
10.2.3.5.5.2. Market
Forecast, 2022 – 2030
10.2.4. Genetic
studies
10.2.4.1. Definition
10.2.4.2. Market Estimation and Penetration, 2015 - 2021
10.2.4.3. Market Forecast, 2022 – 2030
10.2.4.4. Compound Annual Growth Rate (CAGR)
10.2.4.5. Regional Bifurcation
10.2.4.5.1. North America
10.2.4.5.1.1. Market
Estimation, 2015 - 2021
10.2.4.5.1.2. Market
Forecast, 2022 – 2030
10.2.4.5.2. Europe
10.2.4.5.2.1. Market
Estimation, 2015 - 2021
10.2.4.5.2.2. Market
Forecast, 2022 – 2030
10.2.4.5.3. Asia Pacific
10.2.4.5.3.1. Market
Estimation, 2015 - 2021
10.2.4.5.3.2. Market
Forecast, 2022 – 2030
10.2.4.5.4. Middle East and Africa
10.2.4.5.4.1. Market
Estimation, 2015 - 2021
10.2.4.5.4.2. Market
Forecast, 2022 – 2030
10.2.4.5.5. Latin America
10.2.4.5.5.1. Market
Estimation, 2015 - 2021
10.2.4.5.5.2. Market
Forecast, 2022 – 2030
10.2.5. Testicular
biopsy
10.2.5.1. Definition
10.2.5.2. Market Estimation and Penetration, 2015 - 2021
10.2.5.3. Market Forecast, 2022 – 2030
10.2.5.4. Compound Annual Growth Rate (CAGR)
10.2.5.5. Regional Bifurcation
10.2.5.5.1. North America
10.2.5.5.1.1. Market
Estimation, 2015 - 2021
10.2.5.5.1.2. Market
Forecast, 2022 – 2030
10.2.5.5.2. Europe
10.2.5.5.2.1. Market
Estimation, 2015 - 2021
10.2.5.5.2.2. Market
Forecast, 2022 – 2030
10.2.5.5.3. Asia Pacific
10.2.5.5.3.1. Market
Estimation, 2015 - 2021
10.2.5.5.3.2. Market
Forecast, 2022 – 2030
10.2.5.5.4. Middle East and Africa
10.2.5.5.4.1. Market
Estimation, 2015 - 2021
10.2.5.5.4.2. Market
Forecast, 2022 – 2030
10.2.5.5.5. Latin America
10.2.5.5.5.1. Market
Estimation, 2015 - 2021
10.2.5.5.5.2. Market
Forecast, 2022 – 2030
10.3. Key
Segment for Channeling Investments
10.3.1. By
Diagnosis
11. North America Male Hypogonadism Market Analysis and Forecasts, 2022 – 2030
11.1. Overview
11.1.1. North
America Male Hypogonadism Market Revenue
(US$ Mn)
11.2. North
America Male Hypogonadism Market Revenue
(US$ Mn) and Forecasts, By Type
11.2.1. Primary
11.2.1.1. Klinefelter syndrome
11.2.1.2. Mumps orchitis
11.2.1.3. Hemochromatosis
11.2.1.4. Others
11.2.2. Secondary
11.2.2.1. Kallmann’s syndrome
11.2.2.2. Pituitary disorders
11.2.2.3. Inflammatory Diseases
11.2.2.4. Others
11.3. North
America Male Hypogonadism Market Revenue
(US$ Mn) and Forecasts, By Therapy
11.3.1. Testosterone
replacement therapy
11.3.1.1. Topical Gel
11.3.1.2. Injections
11.3.1.3. Implantable pellets.
11.3.1.4. Transdermal Patches
11.3.1.5. Others
11.3.2. Gonadotropin-releasing
hormones therapy
11.4. North
America Male Hypogonadism Market Revenue
(US$ Mn) and Forecasts, By Diagnosis
11.4.1. Hormone
testing
11.4.2. Semen
analysis
11.4.3. Pituitary
imaging
11.4.4. Genetic
studies
11.4.5. Testicular
biopsy
11.5. North
America Male Hypogonadism Market Revenue
(US$ Mn) and Forecasts, By Country
11.5.1. U.S
11.5.1.1. U.S Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Type
11.5.1.1.1. Primary
11.5.1.1.1.1. Klinefelter
syndrome
11.5.1.1.1.2. Mumps
orchitis
11.5.1.1.1.3. Hemochromatosis
11.5.1.1.1.4. Others
11.5.1.1.2. Secondary
11.5.1.1.2.1. Kallmann’s
syndrome
11.5.1.1.2.2. Pituitary
disorders
11.5.1.1.2.3. Inflammatory
Diseases
11.5.1.1.2.4. Others
11.5.1.2. U.S Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Therapy
11.5.1.2.1. Testosterone replacement therapy
11.5.1.2.1.1. Topical
Gel
11.5.1.2.1.2. Injections
11.5.1.2.1.3. Implantable
pellets.
11.5.1.2.1.4. Transdermal
Patches
11.5.1.2.1.5. Others
11.5.1.2.2. Gonadotropin-releasing hormones therapy
11.5.1.3. U.S Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Diagnosis
11.5.1.3.1. Hormone testing
11.5.1.3.2. Semen analysis
11.5.1.3.3. Pituitary imaging
11.5.1.3.4. Genetic studies
11.5.1.3.5. Testicular biopsy
11.5.2. Canada
11.5.2.1. Canada Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Type
11.5.2.1.1. Primary
11.5.2.1.1.1. Klinefelter
syndrome
11.5.2.1.1.2. Mumps
orchitis
11.5.2.1.1.3. Hemochromatosis
11.5.2.1.1.4. Others
11.5.2.1.2. Secondary
11.5.2.1.2.1. Kallmann’s
syndrome
11.5.2.1.2.2. Pituitary
disorders
11.5.2.1.2.3. Inflammatory
Diseases
11.5.2.1.2.4. Others
11.5.2.2. Canada Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Therapy
11.5.2.2.1. Testosterone replacement therapy
11.5.2.2.1.1. Topical
Gel
11.5.2.2.1.2. Injections
11.5.2.2.1.3. Implantable
pellets.
11.5.2.2.1.4. Transdermal
Patches
11.5.2.2.1.5. Others
11.5.2.2.2. Gonadotropin-releasing hormones therapy
11.5.2.3. Canada Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Diagnosis
11.5.2.3.1. Hormone testing
11.5.2.3.2. Semen analysis
11.5.2.3.3. Pituitary imaging
11.5.2.3.4. Genetic studies
11.5.2.3.5. Testicular biopsy
11.5.3. Mexico
11.5.3.1. Mexico Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Type
11.5.3.1.1. Primary
11.5.3.1.1.1. Klinefelter
syndrome
11.5.3.1.1.2. Mumps
orchitis
11.5.3.1.1.3. Hemochromatosis
11.5.3.1.1.4. Others
11.5.3.1.2. Secondary
11.5.3.1.2.1. Kallmann’s
syndrome
11.5.3.1.2.2. Pituitary
disorders
11.5.3.1.2.3. Inflammatory
Diseases
11.5.3.1.2.4. Others
11.5.3.2. Mexico Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Therapy
11.5.3.2.1. Testosterone replacement therapy
11.5.3.2.1.1. Topical
Gel
11.5.3.2.1.2. Injections
11.5.3.2.1.3. Implantable
pellets.
11.5.3.2.1.4. Transdermal
Patches
11.5.3.2.1.5. Others
11.5.3.2.2. Gonadotropin-releasing hormones therapy
11.5.3.3. Mexico Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Diagnosis
11.5.3.3.1. Hormone testing
11.5.3.3.2. Semen analysis
11.5.3.3.3. Pituitary imaging
11.5.3.3.4. Genetic studies
11.5.3.3.5. Testicular biopsy
11.5.4. Rest of
North America
11.5.4.1. Rest of North America Male Hypogonadism Market Revenue (US$ Mn) and Forecasts, By
Type
11.5.4.1.1. Primary
11.5.4.1.1.1. Klinefelter
syndrome
11.5.4.1.1.2. Mumps
orchitis
11.5.4.1.1.3. Hemochromatosis
11.5.4.1.1.4. Others
11.5.4.1.2. Secondary
11.5.4.1.2.1. Kallmann’s
syndrome
11.5.4.1.2.2. Pituitary
disorders
11.5.4.1.2.3. Inflammatory
Diseases
11.5.4.1.2.4. Others
11.5.4.2. Rest of North America Male Hypogonadism Market Revenue (US$ Mn) and Forecasts, By
Therapy
11.5.4.2.1. Testosterone replacement therapy
11.5.4.2.1.1. Topical
Gel
11.5.4.2.1.2. Injections
11.5.4.2.1.3. Implantable
pellets.
11.5.4.2.1.4. Transdermal
Patches
11.5.4.2.1.5. Others
11.5.4.2.2. Gonadotropin-releasing hormones therapy
11.5.4.3. Rest of North America Male Hypogonadism Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
11.5.4.3.1. Hormone testing
11.5.4.3.2. Semen analysis
11.5.4.3.3. Pituitary imaging
11.5.4.3.4. Genetic studies
11.5.4.3.5. Testicular biopsy
11.6. Key
Segment for Channeling Investments
11.6.1. By
Country
11.6.2. By Type
11.6.3. By
Therapy
11.6.4. By
Diagnosis
12. Europe Male Hypogonadism
Market Analysis and Forecasts, 2022 – 2030
12.1. Overview
12.1.1. Europe
Male Hypogonadism Market Revenue (US$
Mn)
12.2. Europe
Male Hypogonadism Market Revenue (US$
Mn) and Forecasts, By Type
12.2.1. Primary
12.2.1.1. Klinefelter syndrome
12.2.1.2. Mumps orchitis
12.2.1.3. Hemochromatosis
12.2.1.4. Others
12.2.2. Secondary
12.2.2.1. Kallmann’s syndrome
12.2.2.2. Pituitary disorders
12.2.2.3. Inflammatory Diseases
12.2.2.4. Others
12.3. Europe
Male Hypogonadism Market Revenue (US$
Mn) and Forecasts, By Therapy
12.3.1. Testosterone
replacement therapy
12.3.1.1. Topical Gel
12.3.1.2. Injections
12.3.1.3. Implantable pellets.
12.3.1.4. Transdermal Patches
12.3.1.5. Others
12.3.2. Gonadotropin-releasing
hormones therapy
12.4. Europe
Male Hypogonadism Market Revenue (US$
Mn) and Forecasts, By Diagnosis
12.4.1. Hormone
testing
12.4.2. Semen
analysis
12.4.3. Pituitary
imaging
12.4.4. Genetic
studies
12.4.5. Testicular
biopsy
12.5. Europe
Male Hypogonadism Market Revenue (US$
Mn) and Forecasts, By Country
12.5.1. France
12.5.1.1. France Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Type
12.5.1.1.1. Primary
12.5.1.1.1.1. Klinefelter
syndrome
12.5.1.1.1.2. Mumps
orchitis
12.5.1.1.1.3. Hemochromatosis
12.5.1.1.1.4. Others
12.5.1.1.2. Secondary
12.5.1.1.2.1. Kallmann’s
syndrome
12.5.1.1.2.2. Pituitary
disorders
12.5.1.1.2.3. Inflammatory
Diseases
12.5.1.1.2.4. Others
12.5.1.2. France Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Therapy
12.5.1.2.1. Testosterone replacement therapy
12.5.1.2.1.1. Topical
Gel
12.5.1.2.1.2. Injections
12.5.1.2.1.3. Implantable
pellets.
12.5.1.2.1.4. Transdermal
Patches
12.5.1.2.1.5. Others
12.5.1.2.2. Gonadotropin-releasing hormones therapy
12.5.1.3. France Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Diagnosis
12.5.1.3.1. Hormone testing
12.5.1.3.2. Semen analysis
12.5.1.3.3. Pituitary imaging
12.5.1.3.4. Genetic studies
12.5.1.3.5. Testicular biopsy
12.5.2. The UK
12.5.2.1. The UK Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Type
12.5.2.1.1. Primary
12.5.2.1.1.1. Klinefelter
syndrome
12.5.2.1.1.2. Mumps
orchitis
12.5.2.1.1.3. Hemochromatosis
12.5.2.1.1.4. Others
12.5.2.1.2. Secondary
12.5.2.1.2.1. Kallmann’s
syndrome
12.5.2.1.2.2. Pituitary
disorders
12.5.2.1.2.3. Inflammatory
Diseases
12.5.2.1.2.4. Others
12.5.2.2. The UK Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Therapy
12.5.2.2.1. Testosterone replacement therapy
12.5.2.2.1.1. Topical
Gel
12.5.2.2.1.2. Injections
12.5.2.2.1.3. Implantable
pellets.
12.5.2.2.1.4. Transdermal
Patches
12.5.2.2.1.5. Others
12.5.2.2.2. Gonadotropin-releasing hormones therapy
12.5.2.3. The UK Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Diagnosis
12.5.2.3.1. Hormone testing
12.5.2.3.2. Semen analysis
12.5.2.3.3. Pituitary imaging
12.5.2.3.4. Genetic studies
12.5.2.3.5. Testicular biopsy
12.5.3. Spain
12.5.3.1. Spain Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Type
12.5.3.1.1. Primary
12.5.3.1.1.1. Klinefelter
syndrome
12.5.3.1.1.2. Mumps
orchitis
12.5.3.1.1.3. Hemochromatosis
12.5.3.1.1.4. Others
12.5.3.1.2. Secondary
12.5.3.1.2.1. Kallmann’s
syndrome
12.5.3.1.2.2. Pituitary
disorders
12.5.3.1.2.3. Inflammatory
Diseases
12.5.3.1.2.4. Others
12.5.3.2. Spain Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Therapy
12.5.3.2.1. Testosterone replacement therapy
12.5.3.2.1.1. Topical
Gel
12.5.3.2.1.2. Injections
12.5.3.2.1.3. Implantable
pellets.
12.5.3.2.1.4. Transdermal
Patches
12.5.3.2.1.5. Others
12.5.3.2.2. Gonadotropin-releasing hormones therapy
12.5.3.3. Spain Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Diagnosis
12.5.3.3.1. Hormone testing
12.5.3.3.2. Semen analysis
12.5.3.3.3. Pituitary imaging
12.5.3.3.4. Genetic studies
12.5.3.3.5. Testicular biopsy
12.5.4. Germany
12.5.4.1. Germany Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Type
12.5.4.1.1. Primary
12.5.4.1.1.1. Klinefelter
syndrome
12.5.4.1.1.2. Mumps
orchitis
12.5.4.1.1.3. Hemochromatosis
12.5.4.1.1.4. Others
12.5.4.1.2. Secondary
12.5.4.1.2.1. Kallmann’s
syndrome
12.5.4.1.2.2. Pituitary
disorders
12.5.4.1.2.3. Inflammatory
Diseases
12.5.4.1.2.4. Others
12.5.4.2. Germany Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Therapy
12.5.4.2.1. Testosterone replacement therapy
12.5.4.2.1.1. Topical
Gel
12.5.4.2.1.2. Injections
12.5.4.2.1.3. Implantable
pellets.
12.5.4.2.1.4. Transdermal
Patches
12.5.4.2.1.5. Others
12.5.4.2.2. Gonadotropin-releasing hormones therapy
12.5.4.3. Germany Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Diagnosis
12.5.4.3.1. Hormone testing
12.5.4.3.2. Semen analysis
12.5.4.3.3. Pituitary imaging
12.5.4.3.4. Genetic studies
12.5.4.3.5. Testicular biopsy
12.5.5. Italy
12.5.5.1. Italy Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Type
12.5.5.1.1. Primary
12.5.5.1.1.1. Klinefelter
syndrome
12.5.5.1.1.2. Mumps
orchitis
12.5.5.1.1.3. Hemochromatosis
12.5.5.1.1.4. Others
12.5.5.1.2. Secondary
12.5.5.1.2.1. Kallmann’s
syndrome
12.5.5.1.2.2. Pituitary
disorders
12.5.5.1.2.3. Inflammatory
Diseases
12.5.5.1.2.4. Others
12.5.5.2. Italy Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Therapy
12.5.5.2.1. Testosterone replacement therapy
12.5.5.2.1.1. Topical
Gel
12.5.5.2.1.2. Injections
12.5.5.2.1.3. Implantable
pellets.
12.5.5.2.1.4. Transdermal
Patches
12.5.5.2.1.5. Others
12.5.5.2.2. Gonadotropin-releasing hormones therapy
12.5.5.3. Italy Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Diagnosis
12.5.5.3.1. Hormone testing
12.5.5.3.2. Semen analysis
12.5.5.3.3. Pituitary imaging
12.5.5.3.4. Genetic studies
12.5.5.3.5. Testicular biopsy
12.5.6. Nordic
Countries
12.5.6.1. Nordic Countries Male Hypogonadism Market Revenue (US$ Mn) and Forecasts, By
Type
12.5.6.1.1. Primary
12.5.6.1.1.1. Klinefelter
syndrome
12.5.6.1.1.2. Mumps
orchitis
12.5.6.1.1.3. Hemochromatosis
12.5.6.1.1.4. Others
12.5.6.1.2. Secondary
12.5.6.1.2.1. Kallmann’s
syndrome
12.5.6.1.2.2. Pituitary
disorders
12.5.6.1.2.3. Inflammatory
Diseases
12.5.6.1.2.4. Others
12.5.6.2. Nordic Countries Male Hypogonadism Market Revenue (US$ Mn) and Forecasts, By
Therapy
12.5.6.2.1. Testosterone replacement therapy
12.5.6.2.1.1. Topical
Gel
12.5.6.2.1.2. Injections
12.5.6.2.1.3. Implantable
pellets.
12.5.6.2.1.4. Transdermal
Patches
12.5.6.2.1.5. Others
12.5.6.2.2. Gonadotropin-releasing hormones therapy
12.5.6.3. Nordic Countries Male Hypogonadism Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
12.5.6.3.1. Hormone testing
12.5.6.3.2. Semen analysis
12.5.6.3.3. Pituitary imaging
12.5.6.3.4. Genetic studies
12.5.6.3.5. Testicular biopsy
12.5.6.4. Nordic Countries Male Hypogonadism Market Revenue (US$ Mn) and Forecasts, By
Country
12.5.6.4.1. Denmark
12.5.6.4.2. Finland
12.5.6.4.3. Iceland
12.5.6.4.4. Sweden
12.5.6.4.5. Norway
12.5.7. Benelux
Union
12.5.7.1. Benelux Union Male Hypogonadism Market Revenue (US$ Mn) and Forecasts, By
Type
12.5.7.1.1. Primary
12.5.7.1.1.1. Klinefelter
syndrome
12.5.7.1.1.2. Mumps
orchitis
12.5.7.1.1.3. Hemochromatosis
12.5.7.1.1.4. Others
12.5.7.1.2. Secondary
12.5.7.1.2.1. Kallmann’s
syndrome
12.5.7.1.2.2. Pituitary
disorders
12.5.7.1.2.3. Inflammatory
Diseases
12.5.7.1.2.4. Others
12.5.7.2. Benelux Union Male Hypogonadism Market Revenue (US$ Mn) and Forecasts, By
Therapy
12.5.7.2.1. Testosterone replacement therapy
12.5.7.2.1.1. Topical
Gel
12.5.7.2.1.2. Injections
12.5.7.2.1.3. Implantable
pellets.
12.5.7.2.1.4. Transdermal
Patches
12.5.7.2.1.5. Others
12.5.7.2.2. Gonadotropin-releasing hormones therapy
12.5.7.3. Benelux Union Male Hypogonadism Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
12.5.7.3.1. Hormone testing
12.5.7.3.2. Semen analysis
12.5.7.3.3. Pituitary imaging
12.5.7.3.4. Genetic studies
12.5.7.3.5. Testicular biopsy
12.5.7.4. Benelux Union Male Hypogonadism Market Revenue (US$ Mn) and Forecasts, By
Country
12.5.7.4.1. Belgium
12.5.7.4.2. The Netherlands
12.5.7.4.3. Luxembourg
12.5.8. Rest of
Europe
12.5.8.1. Rest of Europe Male Hypogonadism Market Revenue (US$ Mn) and Forecasts, By
Type
12.5.8.1.1. Primary
12.5.8.1.1.1. Klinefelter
syndrome
12.5.8.1.1.2. Mumps
orchitis
12.5.8.1.1.3. Hemochromatosis
12.5.8.1.1.4. Others
12.5.8.1.2. Secondary
12.5.8.1.2.1. Kallmann’s
syndrome
12.5.8.1.2.2. Pituitary
disorders
12.5.8.1.2.3. Inflammatory
Diseases
12.5.8.1.2.4. Others
12.5.8.2. Rest of Europe Male Hypogonadism Market Revenue (US$ Mn) and Forecasts, By
Therapy
12.5.8.2.1. Testosterone replacement therapy
12.5.8.2.1.1. Topical
Gel
12.5.8.2.1.2. Injections
12.5.8.2.1.3. Implantable
pellets.
12.5.8.2.1.4. Transdermal
Patches
12.5.8.2.1.5. Others
12.5.8.2.2. Gonadotropin-releasing hormones therapy
12.5.8.3. Rest of Europe Male Hypogonadism Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
12.5.8.3.1. Hormone testing
12.5.8.3.2. Semen analysis
12.5.8.3.3. Pituitary imaging
12.5.8.3.4. Genetic studies
12.5.8.3.5. Testicular biopsy
12.6. Key
Segment for Channeling Investments
12.6.1. By
Country
12.6.2. By Type
12.6.3. By
Therapy
12.6.4. By
Diagnosis
13. Asia Pacific Male Hypogonadism Market Analysis and Forecasts, 2022 – 2030
13.1. Overview
13.1.1. Asia
Pacific Male Hypogonadism Market Revenue
(US$ Mn)
13.2. Asia
Pacific Male Hypogonadism Market Revenue
(US$ Mn) and Forecasts, By Type
13.2.1. Primary
13.2.1.1. Klinefelter syndrome
13.2.1.2. Mumps orchitis
13.2.1.3. Hemochromatosis
13.2.1.4. Others
13.2.2. Secondary
13.2.2.1. Kallmann’s syndrome
13.2.2.2. Pituitary disorders
13.2.2.3. Inflammatory Diseases
13.2.2.4. Others
13.3. Asia
Pacific Male Hypogonadism Market Revenue
(US$ Mn) and Forecasts, By Therapy
13.3.1. Testosterone
replacement therapy
13.3.1.1. Topical Gel
13.3.1.2. Injections
13.3.1.3. Implantable pellets.
13.3.1.4. Transdermal Patches
13.3.1.5. Others
13.3.2. Gonadotropin-releasing
hormones therapy
13.4. Asia
Pacific Male Hypogonadism Market Revenue
(US$ Mn) and Forecasts, By Diagnosis
13.4.1. Hormone
testing
13.4.2. Semen
analysis
13.4.3. Pituitary
imaging
13.4.4. Genetic
studies
13.4.5. Testicular
biopsy
13.5. Asia
Pacific Male Hypogonadism Market Revenue
(US$ Mn) and Forecasts, By Country
13.5.1. China
13.5.1.1. China Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Type
13.5.1.1.1. Primary
13.5.1.1.1.1. Klinefelter
syndrome
13.5.1.1.1.2. Mumps
orchitis
13.5.1.1.1.3. Hemochromatosis
13.5.1.1.1.4. Others
13.5.1.1.2. Secondary
13.5.1.1.2.1. Kallmann’s
syndrome
13.5.1.1.2.2. Pituitary
disorders
13.5.1.1.2.3. Inflammatory
Diseases
13.5.1.1.2.4. Others
13.5.1.2. China Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Therapy
13.5.1.2.1. Testosterone replacement therapy
13.5.1.2.1.1. Topical
Gel
13.5.1.2.1.2. Injections
13.5.1.2.1.3. Implantable
pellets.
13.5.1.2.1.4. Transdermal
Patches
13.5.1.2.1.5. Others
13.5.1.2.2. Gonadotropin-releasing hormones therapy
13.5.1.3. China Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Diagnosis
13.5.1.3.1. Hormone testing
13.5.1.3.2. Semen analysis
13.5.1.3.3. Pituitary imaging
13.5.1.3.4. Genetic studies
13.5.1.3.5. Testicular biopsy
13.5.2. Japan
13.5.2.1. Japan Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Type
13.5.2.1.1. Primary
13.5.2.1.1.1. Klinefelter
syndrome
13.5.2.1.1.2. Mumps
orchitis
13.5.2.1.1.3. Hemochromatosis
13.5.2.1.1.4. Others
13.5.2.1.2. Secondary
13.5.2.1.2.1. Kallmann’s
syndrome
13.5.2.1.2.2. Pituitary
disorders
13.5.2.1.2.3. Inflammatory
Diseases
13.5.2.1.2.4. Others
13.5.2.2. Japan Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Therapy
13.5.2.2.1. Testosterone replacement therapy
13.5.2.2.1.1. Topical
Gel
13.5.2.2.1.2. Injections
13.5.2.2.1.3. Implantable
pellets.
13.5.2.2.1.4. Transdermal
Patches
13.5.2.2.1.5. Others
13.5.2.2.2. Gonadotropin-releasing hormones therapy
13.5.2.3. Japan Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Diagnosis
13.5.2.3.1. Hormone testing
13.5.2.3.2. Semen analysis
13.5.2.3.3. Pituitary imaging
13.5.2.3.4. Genetic studies
13.5.2.3.5. Testicular biopsy
13.5.3. India
13.5.3.1. India Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Type
13.5.3.1.1. Primary
13.5.3.1.1.1. Klinefelter
syndrome
13.5.3.1.1.2. Mumps
orchitis
13.5.3.1.1.3. Hemochromatosis
13.5.3.1.1.4. Others
13.5.3.1.2. Secondary
13.5.3.1.2.1. Kallmann’s
syndrome
13.5.3.1.2.2. Pituitary
disorders
13.5.3.1.2.3. Inflammatory
Diseases
13.5.3.1.2.4. Others
13.5.3.2. India Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Therapy
13.5.3.2.1. Testosterone replacement therapy
13.5.3.2.1.1. Topical
Gel
13.5.3.2.1.2. Injections
13.5.3.2.1.3. Implantable
pellets.
13.5.3.2.1.4. Transdermal
Patches
13.5.3.2.1.5. Others
13.5.3.2.2. Gonadotropin-releasing hormones therapy
13.5.3.3. India Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Diagnosis
13.5.3.3.1. Hormone testing
13.5.3.3.2. Semen analysis
13.5.3.3.3. Pituitary imaging
13.5.3.3.4. Genetic studies
13.5.3.3.5. Testicular biopsy
13.5.4. New
Zealand
13.5.4.1. New Zealand Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Type
13.5.4.1.1. Primary
13.5.4.1.1.1. Klinefelter
syndrome
13.5.4.1.1.2. Mumps
orchitis
13.5.4.1.1.3. Hemochromatosis
13.5.4.1.1.4. Others
13.5.4.1.2. Secondary
13.5.4.1.2.1. Kallmann’s
syndrome
13.5.4.1.2.2. Pituitary
disorders
13.5.4.1.2.3. Inflammatory
Diseases
13.5.4.1.2.4. Others
13.5.4.2. New Zealand Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Therapy
13.5.4.2.1. Testosterone replacement therapy
13.5.4.2.1.1. Topical
Gel
13.5.4.2.1.2. Injections
13.5.4.2.1.3. Implantable
pellets.
13.5.4.2.1.4. Transdermal
Patches
13.5.4.2.1.5. Others
13.5.4.2.2. Gonadotropin-releasing hormones therapy
13.5.4.3. New Zealand Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Diagnosis
13.5.4.3.1. Hormone testing
13.5.4.3.2. Semen analysis
13.5.4.3.3. Pituitary imaging
13.5.4.3.4. Genetic studies
13.5.4.3.5. Testicular biopsy
13.5.5. Australia
13.5.5.1. Australia Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Type
13.5.5.1.1. Primary
13.5.5.1.1.1. Klinefelter
syndrome
13.5.5.1.1.2. Mumps
orchitis
13.5.5.1.1.3. Hemochromatosis
13.5.5.1.1.4. Others
13.5.5.1.2. Secondary
13.5.5.1.2.1. Kallmann’s
syndrome
13.5.5.1.2.2. Pituitary
disorders
13.5.5.1.2.3. Inflammatory
Diseases
13.5.5.1.2.4. Others
13.5.5.2. Australia Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Therapy
13.5.5.2.1. Testosterone replacement therapy
13.5.5.2.1.1. Topical
Gel
13.5.5.2.1.2. Injections
13.5.5.2.1.3. Implantable
pellets.
13.5.5.2.1.4. Transdermal
Patches
13.5.5.2.1.5. Others
13.5.5.2.2. Gonadotropin-releasing hormones therapy
13.5.5.3. Australia Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Diagnosis
13.5.5.3.1. Hormone testing
13.5.5.3.2. Semen analysis
13.5.5.3.3. Pituitary imaging
13.5.5.3.4. Genetic studies
13.5.5.3.5. Testicular biopsy
13.5.6. South
Korea
13.5.6.1. South Korea Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Type
13.5.6.1.1. Primary
13.5.6.1.1.1. Klinefelter
syndrome
13.5.6.1.1.2. Mumps
orchitis
13.5.6.1.1.3. Hemochromatosis
13.5.6.1.1.4. Others
13.5.6.1.2. Secondary
13.5.6.1.2.1. Kallmann’s
syndrome
13.5.6.1.2.2. Pituitary
disorders
13.5.6.1.2.3. Inflammatory
Diseases
13.5.6.1.2.4. Others
13.5.6.2. South Korea Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Therapy
13.5.6.2.1. Testosterone replacement therapy
13.5.6.2.1.1. Topical
Gel
13.5.6.2.1.2. Injections
13.5.6.2.1.3. Implantable
pellets.
13.5.6.2.1.4. Transdermal
Patches
13.5.6.2.1.5. Others
13.5.6.2.2. Gonadotropin-releasing hormones therapy
13.5.6.3. South Korea Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Diagnosis
13.5.6.3.1. Hormone testing
13.5.6.3.2. Semen analysis
13.5.6.3.3. Pituitary imaging
13.5.6.3.4. Genetic studies
13.5.6.3.5. Testicular biopsy
13.5.7. Southeast
Asia
13.5.7.1. Southeast Asia Male Hypogonadism Market Revenue (US$ Mn) and Forecasts, By
Type
13.5.7.1.1. Primary
13.5.7.1.1.1. Klinefelter
syndrome
13.5.7.1.1.2. Mumps
orchitis
13.5.7.1.1.3. Hemochromatosis
13.5.7.1.1.4. Others
13.5.7.1.2. Secondary
13.5.7.1.2.1. Kallmann’s
syndrome
13.5.7.1.2.2. Pituitary
disorders
13.5.7.1.2.3. Inflammatory
Diseases
13.5.7.1.2.4. Others
13.5.7.2. Southeast Asia Male Hypogonadism Market Revenue (US$ Mn) and Forecasts, By
Therapy
13.5.7.2.1. Testosterone replacement therapy
13.5.7.2.1.1. Topical
Gel
13.5.7.2.1.2. Injections
13.5.7.2.1.3. Implantable
pellets.
13.5.7.2.1.4. Transdermal
Patches
13.5.7.2.1.5. Others
13.5.7.2.2. Gonadotropin-releasing hormones therapy
13.5.7.3. Southeast Asia Male Hypogonadism Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
13.5.7.3.1. Hormone testing
13.5.7.3.2. Semen analysis
13.5.7.3.3. Pituitary imaging
13.5.7.3.4. Genetic studies
13.5.7.3.5. Testicular biopsy
13.5.7.4. Southeast Asia Male Hypogonadism Market Revenue (US$ Mn) and Forecasts, By
Country
13.5.7.4.1. Indonesia
13.5.7.4.2. Thailand
13.5.7.4.3. Malaysia
13.5.7.4.4. Singapore
13.5.7.4.5. Rest of Southeast Asia
13.5.8. Rest of
Asia Pacific
13.5.8.1. Rest of Asia Pacific Male Hypogonadism Market Revenue (US$ Mn) and Forecasts, By
Type
13.5.8.1.1. Primary
13.5.8.1.1.1. Klinefelter
syndrome
13.5.8.1.1.2. Mumps
orchitis
13.5.8.1.1.3. Hemochromatosis
13.5.8.1.1.4. Others
13.5.8.1.2. Secondary
13.5.8.1.2.1. Kallmann’s
syndrome
13.5.8.1.2.2. Pituitary
disorders
13.5.8.1.2.3. Inflammatory
Diseases
13.5.8.1.2.4. Others
13.5.8.2. Rest of Asia Pacific Male Hypogonadism Market Revenue (US$ Mn) and Forecasts, By
Therapy
13.5.8.2.1. Testosterone replacement therapy
13.5.8.2.1.1. Topical
Gel
13.5.8.2.1.2. Injections
13.5.8.2.1.3. Implantable
pellets.
13.5.8.2.1.4. Transdermal
Patches
13.5.8.2.1.5. Others
13.5.8.2.2. Gonadotropin-releasing hormones therapy
13.5.8.3. Rest of Asia Pacific Male Hypogonadism Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
13.5.8.3.1. Hormone testing
13.5.8.3.2. Semen analysis
13.5.8.3.3. Pituitary imaging
13.5.8.3.4. Genetic studies
13.5.8.3.5. Testicular biopsy
13.6. Key
Segment for Channeling Investments
13.6.1. By
Country
13.6.2. By Type
13.6.3. By
Therapy
13.6.4. By
Diagnosis
14. Middle East and Africa Male Hypogonadism Market Analysis and Forecasts, 2022 – 2030
14.1. Overview
14.1.1. Middle
East and Africa Male Hypogonadism Market
Revenue (US$ Mn)
14.2. Middle
East and Africa Male Hypogonadism Market
Revenue (US$ Mn) and Forecasts, By Type
14.2.1. Primary
14.2.1.1. Klinefelter syndrome
14.2.1.2. Mumps orchitis
14.2.1.3. Hemochromatosis
14.2.1.4. Others
14.2.2. Secondary
14.2.2.1. Kallmann’s syndrome
14.2.2.2. Pituitary disorders
14.2.2.3. Inflammatory Diseases
14.2.2.4. Others
14.3. Middle
East and Africa Male Hypogonadism Market
Revenue (US$ Mn) and Forecasts, By Therapy
14.3.1. Testosterone
replacement therapy
14.3.1.1. Topical Gel
14.3.1.2. Injections
14.3.1.3. Implantable pellets.
14.3.1.4. Transdermal Patches
14.3.1.5. Others
14.3.2. Gonadotropin-releasing
hormones therapy
14.4. Middle
East and Africa Male Hypogonadism Market
Revenue (US$ Mn) and Forecasts, By Diagnosis
14.4.1. Hormone
testing
14.4.2. Semen
analysis
14.4.3. Pituitary
imaging
14.4.4. Genetic
studies
14.4.5. Testicular
biopsy
14.5. Middle
East and Africa Male Hypogonadism Market
Revenue (US$ Mn) and Forecasts, By Country
14.5.1. Saudi
Arabia
14.5.1.1. Saudi Arabia Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Type
14.5.1.1.1. Primary
14.5.1.1.1.1. Klinefelter
syndrome
14.5.1.1.1.2. Mumps
orchitis
14.5.1.1.1.3. Hemochromatosis
14.5.1.1.1.4. Others
14.5.1.1.2. Secondary
14.5.1.1.2.1. Kallmann’s
syndrome
14.5.1.1.2.2. Pituitary
disorders
14.5.1.1.2.3. Inflammatory
Diseases
14.5.1.1.2.4. Others
14.5.1.2. Saudi Arabia Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Therapy
14.5.1.2.1. Testosterone replacement therapy
14.5.1.2.1.1. Topical
Gel
14.5.1.2.1.2. Injections
14.5.1.2.1.3. Implantable
pellets.
14.5.1.2.1.4. Transdermal
Patches
14.5.1.2.1.5. Others
14.5.1.2.2. Gonadotropin-releasing hormones therapy
14.5.1.3. Saudi Arabia Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Diagnosis
14.5.1.3.1. Hormone testing
14.5.1.3.2. Semen analysis
14.5.1.3.3. Pituitary imaging
14.5.1.3.4. Genetic studies
14.5.1.3.5. Testicular biopsy
14.5.2. UAE
14.5.2.1. UAE Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Type
14.5.2.1.1. Primary
14.5.2.1.1.1. Klinefelter
syndrome
14.5.2.1.1.2. Mumps
orchitis
14.5.2.1.1.3. Hemochromatosis
14.5.2.1.1.4. Others
14.5.2.1.2. Secondary
14.5.2.1.2.1. Kallmann’s
syndrome
14.5.2.1.2.2. Pituitary
disorders
14.5.2.1.2.3. Inflammatory
Diseases
14.5.2.1.2.4. Others
14.5.2.2. UAE Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Therapy
14.5.2.2.1. Testosterone replacement therapy
14.5.2.2.1.1. Topical
Gel
14.5.2.2.1.2. Injections
14.5.2.2.1.3. Implantable
pellets.
14.5.2.2.1.4. Transdermal
Patches
14.5.2.2.1.5. Others
14.5.2.2.2. Gonadotropin-releasing hormones therapy
14.5.2.3. UAE Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Diagnosis
14.5.2.3.1. Hormone testing
14.5.2.3.2. Semen analysis
14.5.2.3.3. Pituitary imaging
14.5.2.3.4. Genetic studies
14.5.2.3.5. Testicular biopsy
14.5.3. Egypt
14.5.3.1. Egypt Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Type
14.5.3.1.1. Primary
14.5.3.1.1.1. Klinefelter
syndrome
14.5.3.1.1.2. Mumps
orchitis
14.5.3.1.1.3. Hemochromatosis
14.5.3.1.1.4. Others
14.5.3.1.2. Secondary
14.5.3.1.2.1. Kallmann’s
syndrome
14.5.3.1.2.2. Pituitary
disorders
14.5.3.1.2.3. Inflammatory
Diseases
14.5.3.1.2.4. Others
14.5.3.2. Egypt Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Therapy
14.5.3.2.1. Testosterone replacement therapy
14.5.3.2.1.1. Topical
Gel
14.5.3.2.1.2. Injections
14.5.3.2.1.3. Implantable
pellets.
14.5.3.2.1.4. Transdermal
Patches
14.5.3.2.1.5. Others
14.5.3.2.2. Gonadotropin-releasing hormones therapy
14.5.3.3. Egypt Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Diagnosis
14.5.3.3.1. Hormone testing
14.5.3.3.2. Semen analysis
14.5.3.3.3. Pituitary imaging
14.5.3.3.4. Genetic studies
14.5.3.3.5. Testicular biopsy
14.5.4. Kuwait
14.5.4.1. Kuwait Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Type
14.5.4.1.1. Primary
14.5.4.1.1.1. Klinefelter
syndrome
14.5.4.1.1.2. Mumps
orchitis
14.5.4.1.1.3. Hemochromatosis
14.5.4.1.1.4. Others
14.5.4.1.2. Secondary
14.5.4.1.2.1. Kallmann’s
syndrome
14.5.4.1.2.2. Pituitary
disorders
14.5.4.1.2.3. Inflammatory
Diseases
14.5.4.1.2.4. Others
14.5.4.2. Kuwait Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Therapy
14.5.4.2.1. Testosterone replacement therapy
14.5.4.2.1.1. Topical
Gel
14.5.4.2.1.2. Injections
14.5.4.2.1.3. Implantable
pellets.
14.5.4.2.1.4. Transdermal
Patches
14.5.4.2.1.5. Others
14.5.4.2.2. Gonadotropin-releasing hormones therapy
14.5.4.3. Kuwait Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Diagnosis
14.5.4.3.1. Hormone testing
14.5.4.3.2. Semen analysis
14.5.4.3.3. Pituitary imaging
14.5.4.3.4. Genetic studies
14.5.4.3.5. Testicular biopsy
14.5.5. South
Africa
14.5.5.1. South Africa Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Type
14.5.5.1.1. Primary
14.5.5.1.1.1. Klinefelter
syndrome
14.5.5.1.1.2. Mumps
orchitis
14.5.5.1.1.3. Hemochromatosis
14.5.5.1.1.4. Others
14.5.5.1.2. Secondary
14.5.5.1.2.1. Kallmann’s
syndrome
14.5.5.1.2.2. Pituitary
disorders
14.5.5.1.2.3. Inflammatory
Diseases
14.5.5.1.2.4. Others
14.5.5.2. South Africa Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Therapy
14.5.5.2.1. Testosterone replacement therapy
14.5.5.2.1.1. Topical
Gel
14.5.5.2.1.2. Injections
14.5.5.2.1.3. Implantable
pellets.
14.5.5.2.1.4. Transdermal
Patches
14.5.5.2.1.5. Others
14.5.5.2.2. Gonadotropin-releasing hormones therapy
14.5.5.3. South Africa Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Diagnosis
14.5.5.3.1. Hormone testing
14.5.5.3.2. Semen analysis
14.5.5.3.3. Pituitary imaging
14.5.5.3.4. Genetic studies
14.5.5.3.5. Testicular biopsy
14.5.6. Rest of
Middle East & Africa
14.5.6.1. Rest of Middle East & Africa Male Hypogonadism Market Revenue (US$ Mn) and Forecasts, By
Type
14.5.6.1.1. Primary
14.5.6.1.1.1. Klinefelter
syndrome
14.5.6.1.1.2. Mumps
orchitis
14.5.6.1.1.3. Hemochromatosis
14.5.6.1.1.4. Others
14.5.6.1.2. Secondary
14.5.6.1.2.1. Kallmann’s
syndrome
14.5.6.1.2.2. Pituitary
disorders
14.5.6.1.2.3. Inflammatory
Diseases
14.5.6.1.2.4. Others
14.5.6.2. Rest of Middle East & Africa Male Hypogonadism Market Revenue (US$ Mn) and Forecasts, By
Therapy
14.5.6.2.1. Testosterone replacement therapy
14.5.6.2.1.1. Topical
Gel
14.5.6.2.1.2. Injections
14.5.6.2.1.3. Implantable
pellets.
14.5.6.2.1.4. Transdermal
Patches
14.5.6.2.1.5. Others
14.5.6.2.2. Gonadotropin-releasing hormones therapy
14.5.6.3. Rest of Middle East & Africa Male Hypogonadism Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
14.5.6.3.1. Hormone testing
14.5.6.3.2. Semen analysis
14.5.6.3.3. Pituitary imaging
14.5.6.3.4. Genetic studies
14.5.6.3.5. Testicular biopsy
14.6. Key
Segment for Channeling Investments
14.6.1. By
Country
14.6.2. By Type
14.6.3. By
Therapy
14.6.4. By
Diagnosis
15. Latin America Male Hypogonadism Market Analysis and Forecasts, 2022 – 2030
15.1. Overview
15.1.1. Latin
America Male Hypogonadism Market Revenue
(US$ Mn)
15.2. Latin
America Male Hypogonadism Market Revenue
(US$ Mn) and Forecasts, By Type
15.2.1. Primary
15.2.1.1. Klinefelter syndrome
15.2.1.2. Mumps orchitis
15.2.1.3. Hemochromatosis
15.2.1.4. Others
15.2.2. Secondary
15.2.2.1. Kallmann’s syndrome
15.2.2.2. Pituitary disorders
15.2.2.3. Inflammatory Diseases
15.2.2.4. Others
15.3. Latin
America Male Hypogonadism Market Revenue
(US$ Mn) and Forecasts, By Therapy
15.3.1. Testosterone
replacement therapy
15.3.1.1. Topical Gel
15.3.1.2. Injections
15.3.1.3. Implantable pellets.
15.3.1.4. Transdermal Patches
15.3.1.5. Others
15.3.2. Gonadotropin-releasing
hormones therapy
15.4. Latin
America Male Hypogonadism Market Revenue
(US$ Mn) and Forecasts, By Diagnosis
15.4.1. Hormone
testing
15.4.2. Semen
analysis
15.4.3. Pituitary
imaging
15.4.4. Genetic
studies
15.4.5. Testicular
biopsy
15.5. Latin
America Male Hypogonadism Market Revenue
(US$ Mn) and Forecasts, By Country
15.5.1. Brazil
15.5.1.1. Brazil Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Type
15.5.1.1.1. Primary
15.5.1.1.1.1. Klinefelter
syndrome
15.5.1.1.1.2. Mumps
orchitis
15.5.1.1.1.3. Hemochromatosis
15.5.1.1.1.4. Others
15.5.1.1.2. Secondary
15.5.1.1.2.1. Kallmann’s
syndrome
15.5.1.1.2.2. Pituitary
disorders
15.5.1.1.2.3. Inflammatory
Diseases
15.5.1.1.2.4. Others
15.5.1.2. Brazil Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Therapy
15.5.1.2.1. Testosterone replacement therapy
15.5.1.2.1.1. Topical
Gel
15.5.1.2.1.2. Injections
15.5.1.2.1.3. Implantable
pellets.
15.5.1.2.1.4. Transdermal
Patches
15.5.1.2.1.5. Others
15.5.1.2.2. Gonadotropin-releasing hormones therapy
15.5.1.3. Brazil Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Diagnosis
15.5.1.3.1. Hormone testing
15.5.1.3.2. Semen analysis
15.5.1.3.3. Pituitary imaging
15.5.1.3.4. Genetic studies
15.5.1.3.5. Testicular biopsy
15.5.2. Argentina
15.5.2.1. Argentina Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Type
15.5.2.1.1. Primary
15.5.2.1.1.1. Klinefelter
syndrome
15.5.2.1.1.2. Mumps
orchitis
15.5.2.1.1.3. Hemochromatosis
15.5.2.1.1.4. Others
15.5.2.1.2. Secondary
15.5.2.1.2.1. Kallmann’s
syndrome
15.5.2.1.2.2. Pituitary
disorders
15.5.2.1.2.3. Inflammatory
Diseases
15.5.2.1.2.4. Others
15.5.2.2. Argentina Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Therapy
15.5.2.2.1. Testosterone replacement therapy
15.5.2.2.1.1. Topical
Gel
15.5.2.2.1.2. Injections
15.5.2.2.1.3. Implantable
pellets.
15.5.2.2.1.4. Transdermal
Patches
15.5.2.2.1.5. Others
15.5.2.2.2. Gonadotropin-releasing hormones therapy
15.5.2.3. Argentina Male Hypogonadism
Market Revenue (US$ Mn) and Forecasts, By Diagnosis
15.5.2.3.1. Hormone testing
15.5.2.3.2. Semen analysis
15.5.2.3.3. Pituitary imaging
15.5.2.3.4. Genetic studies
15.5.2.3.5. Testicular biopsy
15.5.3. Rest of
Latin America
15.5.3.1. Rest of Latin America Male Hypogonadism Market Revenue (US$ Mn) and Forecasts, By
Type
15.5.3.1.1. Primary
15.5.3.1.1.1. Klinefelter
syndrome
15.5.3.1.1.2. Mumps
orchitis
15.5.3.1.1.3. Hemochromatosis
15.5.3.1.1.4. Others
15.5.3.1.2. Secondary
15.5.3.1.2.1. Kallmann’s
syndrome
15.5.3.1.2.2. Pituitary
disorders
15.5.3.1.2.3. Inflammatory
Diseases
15.5.3.1.2.4. Others
15.5.3.2. Rest of Latin America Male Hypogonadism Market Revenue (US$ Mn) and Forecasts, By
Therapy
15.5.3.2.1. Testosterone replacement therapy
15.5.3.2.1.1. Topical
Gel
15.5.3.2.1.2. Injections
15.5.3.2.1.3. Implantable
pellets.
15.5.3.2.1.4. Transdermal
Patches
15.5.3.2.1.5. Others
15.5.3.2.2. Gonadotropin-releasing hormones therapy
15.5.3.3. Rest of Latin America Male Hypogonadism Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
15.5.3.3.1. Hormone testing
15.5.3.3.2. Semen analysis
15.5.3.3.3. Pituitary imaging
15.5.3.3.4. Genetic studies
15.5.3.3.5. Testicular biopsy
15.6. Key
Segment for Channeling Investments
15.6.1. By
Country
15.6.2. By Type
15.6.3. By
Therapy
15.6.4. By
Diagnosis
16. Competitive Benchmarking
16.1. Brand
Benchmarking
16.2. Market
Share Analysis, 2021
16.3. Global
Presence and Growth Strategies
16.3.1. Mergers
and Acquisitions
16.3.2. Product
Launches
16.3.3. Investments
Trends
16.3.4. R&D
Initiatives
17. Player Profiles
17.1. AbbVie
17.1.1. Company
Details
17.1.2. Company
Overview
17.1.3. Product
Offerings
17.1.4. Key
Developments
17.1.5. Financial
Analysis
17.1.6. SWOT
Analysis
17.1.7. Business
Strategies
17.2. Antares
Pharma, Inc.
17.2.1. Company
Details
17.2.2. Company
Overview
17.2.3. Product
Offerings
17.2.4. Key
Developments
17.2.5. Financial
Analysis
17.2.6. SWOT
Analysis
17.2.7. Business
Strategies
17.3. Aytu
BioScience, Inc.
17.3.1. Company
Details
17.3.2. Company
Overview
17.3.3. Product
Offerings
17.3.4. Key
Developments
17.3.5. Financial
Analysis
17.3.6. SWOT
Analysis
17.3.7. Business
Strategies
17.4. Clarus
Therapeutics, Inc.
17.4.1. Company
Details
17.4.2. Company
Overview
17.4.3. Product
Offerings
17.4.4. Key
Developments
17.4.5. Financial
Analysis
17.4.6. SWOT
Analysis
17.4.7. Business
Strategies
17.5. Eli Lilly
and Company
17.5.1. Company
Details
17.5.2. Company
Overview
17.5.3. Product
Offerings
17.5.4. Key
Developments
17.5.5. Financial
Analysis
17.5.6. SWOT
Analysis
17.5.7. Business
Strategies
17.6. Endo
Pharmaceuticals
17.6.1. Company
Details
17.6.2. Company
Overview
17.6.3. Product
Offerings
17.6.4. Key
Developments
17.6.5. Financial
Analysis
17.6.6. SWOT
Analysis
17.6.7. Business
Strategies
17.7. Merck
& Co. Inc.
17.7.1. Company
Details
17.7.2. Company
Overview
17.7.3. Product
Offerings
17.7.4. Key
Developments
17.7.5. Financial
Analysis
17.7.6. SWOT
Analysis
17.7.7. Business
Strategies
17.8. Pharmacia
& Upjohn Co. (Pfizer Inc.)
17.8.1. Company
Details
17.8.2. Company
Overview
17.8.3. Product
Offerings
17.8.4. Key
Developments
17.8.5. Financial
Analysis
17.8.6. SWOT
Analysis
17.8.7. Business
Strategies
17.9. Teva
Pharmaceutical Industries Ltd.
17.9.1. Company
Details
17.9.2. Company
Overview
17.9.3. Product
Offerings
17.9.4. Key
Developments
17.9.5. Financial
Analysis
17.9.6. SWOT
Analysis
17.9.7. Business
Strategies
17.10. Upsher-Smith
Laboratories, LLC.
17.10.1. Company
Details
17.10.2. Company
Overview
17.10.3. Product
Offerings
17.10.4. Key
Developments
17.10.5. Financial
Analysis
17.10.6. SWOT
Analysis
17.10.7. Business
Strategies
18. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User
and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
